These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 22206637)

  • 1. In-hospital death while awaiting cardioverter/defibrillator in neuromuscular disease.
    Stöllberger C; Steger C; Sehnal E; Finsterer J
    Int J Cardiol; 2012 Aug; 159(2):e39-40. PubMed ID: 22206637
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiac devices and neuromuscular disorders in left ventricular noncompaction.
    Stöllberger C; Keller H; Blazek G; Bichler K; Wegner C; Finsterer J
    Int J Cardiol; 2011 Apr; 148(1):120-3. PubMed ID: 21334754
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful termination of a ventricular arrhythmia by implantable cardioverter defibrillator therapy in a patient with cardiac amyloidosis: insight into mechanisms of sudden death.
    Lin G; Dispenzieri A; Brady PA
    Eur Heart J; 2010 Jun; 31(12):1538. PubMed ID: 20061577
    [No Abstract]   [Full Text] [Related]  

  • 4. [Arrhythmias in cardiomyopathies].
    Kaneko Y; Kurabayashi M
    Nihon Rinsho; 2002 Jul; 60(7):1434-9. PubMed ID: 12136626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Audible implantable cardioverter defibrillator alarms detect intermittent conductor discontinuity.
    Sheth N; Mahmood K; Singh B; Carter-Adkins D; Pachulski RT
    Can J Cardiol; 2002 Apr; 18(4):430-2. PubMed ID: 11992137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?
    Ellenbogen KA; Levine JH; Berger RD; Daubert JP; Winters SL; Greenstein E; Shalaby A; Schaechter A; Subacius H; Kadish A;
    Circulation; 2006 Feb; 113(6):776-82. PubMed ID: 16461817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of implantable intracardiac defibrillators in patients with cardiac immunoglobulin light chain amyloidosis.
    Rezk T; Whelan CJ; Lachmann HJ; Fontana M; Sachchithanantham S; Mahmood S; Khan F; Khiani R; Tomson J; Youngstein T; Gillmore JD; Hawkins PN; Wechalekar AD
    Br J Haematol; 2018 Jul; 182(1):145-148. PubMed ID: 28485005
    [No Abstract]   [Full Text] [Related]  

  • 8. Implantable cardioverter defibrillator therapy for non-ischaemic cardiomyopathy. What is the role of programmed electrical stimulation?
    Plummer C
    Europace; 2009 Mar; 11(3):273-5. PubMed ID: 19164361
    [No Abstract]   [Full Text] [Related]  

  • 9. Defibrillator implantation for the primary prevention of sudden death in patients awaiting cardiac transplantation: one center's experience.
    Bastante Valiente T; Cano MJ; Delgado JF; Gil ML; Arribas F; Sánchez MA; Cortina J; Sáenz de la Calzada C
    Rev Esp Cardiol; 2011 Mar; 64(3):240-2. PubMed ID: 21315501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials.
    Ghanbari H; Dalloul G; Hasan R; Daccarett M; Saba S; David S; Machado C
    Arch Intern Med; 2009 Sep; 169(16):1500-6. PubMed ID: 19752408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implantable cardioverter-defibrillators in hypertrophic cardiomyopathy.
    Vieira AP; Adragão PP; Santos KR; Morgado FB; Cavaco DM; Rossi R; Abecasis M; Neves JP; Bonhosrst D; Gomes JL; Gomes RS
    Rev Port Cardiol; 2005 Mar; 24(3):407-15. PubMed ID: 15929624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implantable cardioverter defibrillators and quality of life: results from the defibrillators in nonischemic cardiomyopathy treatment evaluation study.
    Passman R; Subacius H; Ruo B; Schaechter A; Howard A; Sears SF; Kadish A
    Arch Intern Med; 2007 Nov; 167(20):2226-32. PubMed ID: 17998496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death.
    Tung R; Zimetbaum P; Josephson ME
    J Am Coll Cardiol; 2008 Sep; 52(14):1111-21. PubMed ID: 18804736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implantable cardioverter defibrillator criteria for primary and secondary prevention of pediatric sudden cardiac death.
    Berul CI
    Pacing Clin Electrophysiol; 2009 Jul; 32 Suppl 2():S67-70. PubMed ID: 19602167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The ABCD (Alternans Before Cardioverter Defibrillator) Trial: strategies using T-wave alternans to improve efficiency of sudden cardiac death prevention.
    Costantini O; Hohnloser SH; Kirk MM; Lerman BB; Baker JH; Sethuraman B; Dettmer MM; Rosenbaum DS;
    J Am Coll Cardiol; 2009 Feb; 53(6):471-9. PubMed ID: 19195603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Implantable cardioverter-defibrillator: present and future indications.
    Block M; Scheld H; Breithardt G
    Arch Mal Coeur Vaiss; 1996 Feb; 89 Spec No 1():141-7. PubMed ID: 8734176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Implantable cardioverter-defibrillators in patients resuscitated from sudden death and in patients with sustained refractory ventricular tachycardia].
    Adragão P; Parreira L; Neves J; Morgado F; Abecassis M; Almeida M; Martins D; Bonhorst D; Seabra-Gomes R
    Rev Port Cardiol; 1996 Mar; 15(3):195-206, 179, 181. PubMed ID: 8634168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implantable cardioverter defibrillator prevents sudden cardiac death in systemic sclerosis.
    Bernardo P; Conforti ML; Bellando-Randone S; Pieragnoli P; Blagojevic J; Kaloudi O; Guiducci S; Porta F; Padeletti L; Gensini GF; Matucci-Cerinic M
    J Rheumatol; 2011 Aug; 38(8):1617-21. PubMed ID: 21632680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infarct tissue heterogeneity assessed with contrast-enhanced MRI predicts spontaneous ventricular arrhythmia in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator.
    Roes SD; Borleffs CJ; van der Geest RJ; Westenberg JJ; Marsan NA; Kaandorp TA; Reiber JH; Zeppenfeld K; Lamb HJ; de Roos A; Schalij MJ; Bax JJ
    Circ Cardiovasc Imaging; 2009 May; 2(3):183-90. PubMed ID: 19808591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular considerations in the management of neuromuscular disease.
    Ishikawa Y; Bach JR; Sarma RJ; Tamura T; Song J; Marra SW; Ishikawa Y; Minami R
    Semin Neurol; 1995 Mar; 15(1):93-108. PubMed ID: 7638466
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.